Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM035324
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients : a randomized, double-blind, placebo-controlled trial / H. P. Bhattoa, P. Bettembuk, A. Balogh, Gy. Szegedi, E. Kiss
Dátum:2004
ISSN:0937941X
Megjegyzések:We studied the effect of 1-year transdermal estrogen replacement therapy (ERT) on bone mineral density (BMD) and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus (SLE) patients in a randomized, double-blind, placebo-controlled trial. SLE patients were randomly allocated to treatment (estradiol; 50 ??g transdermal 17??-estradiol; n = 15) or placebo (n = 17) group. Both groups received 5 mg continuous oral medroxyprogesterone acetate, 500 mg calcium and 400 IU vitamin D3, L1-L4 spine (LS), left femur and total hip BMD were measured at baseline and at 6 and 12 months. Serum osteocalcin (OC) and degradation products of C-terminal telopeptides of type-I collagen (CTx) levels were measured at baseline and 3, 6, 9, and 12 months. There was a significant difference in the percentage change of LS BMD at 6 months between the two groups (103.24 ?? 3.74% (estradiol group) vs 98.99 ?? 3.11% (placebo group); P < 0.005). There was a significant decrease within the estradiol group in the CTx levels between baseline and all subsequent visits (P < 0.05). There was no significant difference in SLE disease activity index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) damage index and corticosteroid dose during the study period, Transdermal estradiol may prevent bone loss in postmenopausal SLE women at the lumbar spine and femur, with no increase in disease activity among postmenopausal SLE women receiving transdermal ERT. The high dropout rate (8/15) leads us to the conclusion that efficacy of HRT in a high-risk group such as SLE women can be attained only in a small number of patients, provided all inclusion/exclusion criteria are strictly adhered to.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Biochemical markers of bone turnover
Bone mineral density
Osteopenia
Postmenopausal Systemic lupus erythematosus
Transdermal estrogen replacement therapy
biological marker
calcium
carboxy terminal telopeptide
collagen type 1
corticosteroid
estradiol
medroxyprogesterone acetate
osteocalcin
placebo
vitamin D
adult
aged
article
bone density
bone mineral
bone turnover
carboxy terminal sequence
clinical trial
controlled clinical trial
controlled study
disease activity
double blind procedure
drug effect
drug efficacy
estrogen therapy
female
femur
hip
human
lumbar spine
medical society
osteolysis
osteopenia
postmenopause
priority journal
prophylaxis
protein blood level
randomization
randomized controlled trial
systemic lupus erythematosus
Administration, Cutaneous
Adult
Aged
Biological Markers
Bone Density
Bone Remodeling
Double-Blind Method
Estradiol
Estrogen Replacement Therapy
Female
Femur Neck
Hip Joint
Humans
Lumbar Vertebrae
Lupus Erythematosus, Systemic
Middle Aged
Osteoporosis, Postmenopausal
egyetemen (Magyarországon) készült közlemény
Megjelenés:Osteoporosis International. - 15 : 5 (2004), p. 396-404. -
További szerzők:Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1